leisure time -WSS

leisure time

author：focus 2025-10-02 22:23:52 - browse：519

Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT — The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients.

A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons.

NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Astellas still sees hope in its gene therapy after four deaths

leisure time

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Hospitals look to new technology to keep health care workers safe

Anthos stroke drug appears safer than common blood thinner

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Digital health funding stays low as a new reality sets in

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

hotspot

leisure time

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Bright Health sells Medicare Advantage business to Molina

CRISPR pioneers react to Casgevy, first gene

Medical leaders decry Supreme Court decision on affirmative action

Why medical students are struggling with mental health

State Dept. review finds Biden bears some blame for Afghanistan failures

Digital health funding stays low as a new reality sets in

United colonoscopy coverage change 'may cost lives,' doctors say

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

hotspot

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Anthos stroke drug appears safer than common blood thinner

Sickle cell gene therapy cures need to be accessible in Africa

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

EU fines Illumina $475 million over Grail acquisition

focus

leisure time

explore

leisure time